Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Gender) |
(→Gender) |
||
| Line 52: | Line 52: | ||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | ||
===Gender=== | ===Gender=== | ||
*HUS affects woman(59%) more than man(41%) . | *HUS affects woman(59%) more than man(41%) .<ref>{{Cite journal | ||
| author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]] | |||
| title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes | |||
| journal = [[American journal of hematology]] | |||
| volume = 85 | |||
| issue = 11 | |||
| pages = 844–847 | |||
| year = 2010 | |||
| month = November | |||
| doi = 10.1002/ajh.21833 | |||
| pmid = 20799358 | |||
}}</ref> | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | *[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | ||
Revision as of 20:25, 27 July 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics |
|
FDA on Hemolytic-uremic syndrome epidemiology and demographics |
|
CDC on Hemolytic-uremic syndrome epidemiology and demographics |
|
Hemolytic-uremic syndrome epidemiology and demographics in the news |
|
Blogs on Hemolytic-uremic syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.[1]
- In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals worldwide.[2]
Prevalence.
- The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.[1]
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In 2017, the incidence of hemolytic uremic syndrome (HUS) is approximately 10% .[3]
- The case-fatality mortality rate of HUS is approximately 25%.[4]
Age
- Patients of all age groups may develop hemolytic uremic syndrome (HUS).
- The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[2]
- HUS commonly affects individuals younger 5 older than [number of years] years of age.[2]
- [Chronic isease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- HUS affects woman(59%) more than man(41%) .[5]
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.
- ↑ 2.0 2.1 2.2 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
- ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter
|month=ignored (help) - ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter
|month=ignored (help) - ↑ Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter
|month=ignored (help)